According to preliminary figures, after three quarters Biofrontera has a turnover between 20.8 million euros and 21.0 million euros. In the previous year it was 19.1 million euros. The increase in sales is therefore 9 percent. In the third quarter, sales are between EUR 4.7 million and EUR 4.9 million. That is a decrease of around 9 percent compared to the previous year.
In the USA 2.7 million euros to 2.9 million euros are converted, which is a minus of 19 percent. This is where the crisis is having a clear impact on the market. In Germany, sales rose by around 36 percent to between EUR 1.5 million and EUR 1.7 million. In the rest of Europe, sales decreased by around 15 percent to EUR 0.3 million to EUR 0.5 million.
The fourth quarter is traditionally particularly strong at Biofrontera, and nothing should change in 2020.
More about biotech stocks on 4investors: click here
At a glance – chart and news: Biofrontera